{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.89","upperLimit":"1.19","value":"1.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"A test dose of IV busulfan 0.8 mg/kg was infused at Baseline (Day -12 to -9) to verify a target busulfan integrated AUC of 20,000 μM\\*min with a range of 16,000 to 24,000. If necessary the dose could be adjusted. The PK-directed dose recommendation based on the test dose was administered at Day -5. Blood samples for PK analysis were collected at 0, 15, 30 minutes after the End of Infusion and 240, 300, 360 minutes after start of the infusion. Gas chromatography with mass selective detection (GC-MS) was used to determine the busulfan level in plasma. The ratio was calculated: AUC/Target AUC.","dispersionType":"Full Range","groups":[{"description":"Intravenous (IV) busulfan was administered as a single daily 3-hour continuous infusion based on the PK-directed dose recommendation for 4 days beginning on Day -5 followed by a single bortezomib 1.3 mg/m\\^2 dose administered as a 3 to 5-second bolus IV injection on Day -1 prior to HSCT.","id":"OG000","title":"IV Busulfan"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population included all participants who received the PK-directed IV busulfan followed by autologous HSCT.","reportingStatus":"POSTED","timeFrame":"Baseline (Day -12 to -9), Day -5","title":"Ratio Area Under Curve (AUC)/Target AUC","type":"SECONDARY","unitOfMeasure":"Ratio"}